Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $313,454.45 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ COLL traded down $0.53 during mid-day trading on Thursday, reaching $29.10. 271,093 shares of the company were exchanged, compared to its average volume of 422,183. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The stock has a market capitalization of $916.24 million, a P/E ratio of 12.54 and a beta of 0.99. The company’s 50-day simple moving average is $30.85 and its 200-day simple moving average is $33.08. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in COLL. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. TD Private Client Wealth LLC boosted its holdings in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares in the last quarter. KBC Group NV boosted its holdings in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares in the last quarter. Virtus Fund Advisers LLC raised its position in shares of Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on COLL. Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.